Anticancer agents: Tumor cell growth inhibitory activity and binary QSAR analysis

Current Pharmaceutical Design

Volumn 10, Issue 12, 2004, Pages 1399-1415

  Ren, Steven S ^a,b   Lien, Eric J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Maxim Pharmaceuticals Inc   (United States)

Author keywords

And tumor cell growth inhibitory activity; Anticancer agents; Binary QSAR; Molecular weight; QSAR

Indexed keywords

2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE; 6 DIAZO 5 OXONORLEUCINE; 6 O METHYLGUANINE; ALTRETAMINE; ANTINEOPLASTIC AGENT; BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; FLOXURIDINE; FLUOROURACIL; GUANAZOLE; HYDROXYUREA; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; MITOGUAZONE; MITOMYCIN C; N METHYLFORMAMIDE; PIPOBROMAN; TESTOLACTONE; THIOTEPA; THYMIDINE; TIOGUANINE; TRETAMINE; UNINDEXED DRUG; VINBLASTINE SULFATE;

CANCER CENTER; CANCER INHIBITION; DATA ANALYSIS; DRUG ACTIVITY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TUMOR CELL;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; GROWTH INHIBITORS; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2342417420     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384925     Document Type: Review

References (28)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Adv Drug Delivery Rev 1997; 23: 3.
2. Brustle M, Beck B, Schindler T, King W, Mitchell T, Clark T. J Med Chem 2002; 45: 3345.
3. Hansch C, Leo A. Exploring QSAR Fundamental and Applications in Chemistry and Biology. American Chemical Society: Washington, DC, 1995.
4. Lien EJ. J Clin Hosp Pharm 1982; 7: 101.
5. Wang W, Lien EJ, Lee VHL. In Studies in Physical and Theoretical Chemistry, Graovac, A, Ed, Elsevier Science B.V.: Amsterdam, 1989; Vol. 63: pp. 245-254.
6. Tai AW, Lien EJ. Acta Pharm Jugoslav 1980; 30: 171.
7. Lien EJ. Prog Drug Res 1985; 29: 67.
8. Selassie CD, Wang PH, Lien EJ. Acta Pharm Jugoslav 1980; 30: 135.
9. Lien EJ, Lien LL, Gao H. In QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications, Sanz F, Giraldo J, Manaut F, Eds, Prous Science: Barcelona, Spain, 1995; pp. 94-100.
10. Lien EJ, Gao H. Pharm Res 1995; 12: 583.
11. Ren SJ, Das A, Lien EJ. J Drug Target 1996; 4: 103.
12. Ren SJ, Lien EJ. Prog Drug Res 2000; 54: 1.
13. http://dtp.nci.nih.gov
14. Gao H, Williams C, Labute P, Bajorath J. J Chem Inf Comput Sci 1999; 39: 164.
15. Labute, P. In Proceeding of the 1999 Pacific Symposium on Biocomputing, World Scientific Publishing: River Edge, 1999; pp. 444-455.
16. Chemical Computing Group Inc. MOE 2001.01, 1010 Sherbrooke Street West, Suite 910, Montreal, Quebec, Canada H3A 2R7.
17. Ertl P, Rohde B, Selzer P. J Med Chem 2000; 43: 3714.
18. Wildman SA, Crippen GM. J Chem Inf Comput Sci 1999; 39: 868.
19. Coty C. Drug Discovery Development 2002; 5(8): 67.
20. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. J Med Chem 2002; 45: 2615.
21. Lien EJ, Wang PH. J Pharm Sci 1980; 69: 648.
22. Lien EJ. SAR: Side Effects and Drug Design, Marcel Dekker: New York, 1987.
23. Boyd MR, Paull KD, Rubinstein LR. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, Vleriote FA, Corbett TH, Baker LH, Eds. Kluwer Academic: Hingham, MA, 1992; pp. 11-34.
24. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR. J Natl Cancer Inst 1989; 81: 1088.
25. Paull KD, Lin CM, Malspeis L, Hamel E. Cancer Res 1992; 52: 3892.
26. Anderson WF, Umar A, Viner JL, and Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
27. McGuire JJ. Anticancer antifolates: current status and future directions. Curr Pharm Design 2003; 9(31): 2593-613.
28. Mekenyan O. Dynamic QSAR techniques: applications in drug design and toxicology. Curr Pharm Design 2002; 8(17): 1605-21.